[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Innate Pharma S.A. ADR (IPHA)

Innate Pharma S.A. ADR (IPHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Outcome of Innate Pharma’s 2026 Annual General Meeting

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced the voting results of its shareholders...

IPHA : 1.8000 (-0.55%)
Innate Pharma to participate in the Jefferies Global Healthcare Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing...

IPHA : 1.8000 (-0.55%)
Innate Pharma Q1 Earnings Call Highlights

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502...

IPHA : 1.8000 (-0.55%)
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including...

IPHA : 1.8000 (-0.55%)
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers...

IPHA : 1.8000 (-0.55%)
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announces that the Company will hold a conference...

IPHA : 1.8000 (-0.55%)
Innate Pharma to Participate in the D. Boral Capital Global Conference

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing...

IPHA : 1.8000 (-0.55%)
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and chemotherapy...

IPHA : 1.8000 (-0.55%)
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers...

IPHA : 1.8000 (-0.55%)
Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company "), announced today that Yannis Morel, Chief Operating Officer,...

IPHA : 1.8000 (-0.55%)

Barchart Exclusives

Will Silver’s Price Action be a Bucking Bronco?
Silver’s price remains above the 1980 high, a long-term technical resistance level that has become critical support. At around $62 per ounce, silver is digesting its parabolic price action that took the price over $120 per ounce before correcting. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.